Scholar Rock Holding

Executive Summary

Scholar Rock Holding (SRRK) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that selectively inhibit the activation of growth factors in the TGFβ superfamily. Its lead asset, apitegromab, is a selective myostatin inhibitor currently in Phase 3 for spinal muscular atrophy (SMA) and Phase 2 for facioscapulohumeral muscular dystrophy (FSHD). The company has also explored apitegromab in obesity, with a Phase 2 trial completed in mid-2025, and is advancing SRK-439, a myostatin inhibitor for muscle preservation, into Phase 1. Scholar Rock's platform enables targeted inhibition of latent growth factors, potentially improving efficacy and safety. The company's near-term value is tied to clinical data readouts and regulatory milestones, particularly for apitegromab in SMA and emerging programs in FSHD and obesity. Despite competition in the myostatin space, Scholar Rock's selective approach and diversified pipeline position it for potential upside if upcoming data prove positive.

Upcoming Catalysts (preview)

• H2 2027Phase 2 FSHD trial data for apitegromab50% success
• Q4 2025Phase 2 obesity trial (apitegromab + tirzepatide) data readout60% success
• Q3 2026Phase 1 SRK-439 healthy volunteer trial top-line results75% success